Login / Signup
No change in small low-density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial.
Tsutomu Hirano
Published in:
Journal of diabetes investigation (2023)
Keyphrases
</>
phase iii
study protocol
phase ii
clinical trial
open label